{"entity":{"id":"philip-greenberg","kind":"person","name":"Philip D. Greenberg","aka":[],"tldr":"Immunologist who spent four decades engineering T cells to attack leukaemia and solid tumours.","summary":"Philip Greenberg is Head of the Program in Immunology at Fred Hutchinson Cancer Center and a past president of the American Association for Cancer Research (AACR). An immunologist who has spent four decades engineering T cells to attack leukaemia and solid tumours, he pioneered T-cell receptor-engineered cell therapy, including WT1-specific TCR-T for acute myeloid leukaemia after transplant and mesothelin-directed TCR-T for pancreatic cancer. His papers include a Nature Medicine report that T cell receptor gene therapy targeting WT1 prevents acute myeloid leukaemia relapse after transplant and an Advances in Immunology review of the mechanisms by which adoptively transferred T cells recognise and eliminate tumour cells. His work spans TCR-T and CAR-T cell therapy.","asOf":"2026-09-08","links":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Philip%20D.%20Greenberg"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Greenberg%20PD%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Philip%20D.%20Greenberg"}],"tags":[],"related":[],"cancers":["aml","pancreatic"],"sections":[],"technologies":["tcr-t","car-t"],"targets":["mesothelin"],"drugs":[],"companies":[],"institutions":["fred-hutch","aacr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head, Program in Immunology, Fred Hutchinson Cancer Center","institutionId":"fred-hutch","specialisms":["T-cell immunotherapy","TCR-T","Leukaemia"],"profiles":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Philip%20D.%20Greenberg"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Greenberg%20PD%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Philip%20D.%20Greenberg"}],"papers":[{"title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","journal":"Nature Medicine","year":2019,"url":"https://doi.org/10.1038/s41591-019-0472-9","doi":"10.1038/s41591-019-0472-9"},{"title":"Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells","journal":"Advances in Immunology","year":1991,"url":"https://doi.org/10.1016/s0065-2776(08)60778-6","doi":"10.1016/s0065-2776(08)60778-6"}],"orcid":"0000-0003-3812-647X"},"route":"/people/philip-greenberg/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}],"target":[{"id":"mesothelin","kind":"target","name":"Mesothelin","route":"/targets/mesothelin/"}],"institution":[{"id":"aacr","kind":"institution","name":"American Association for Cancer Research (AACR)","route":"/institutions/aacr/"},{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/"}]}}